Rio Tinto PLC ADS (RIO) Financials Nov 14, 2014, 5:25

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
Rio Tinto PLC ADS (RIO) Financials Nov 14, 2014, 5:25 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Rio Tinto PLC ADS


Fiscal year is January-December. All values GBP millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 26.8B 35.73B 37.76B 32.15B 32.74B
Cost of Goods Sold (COGS) incl. D&A 21.52B 19.47B 17.48B 17.65B 16.47B
COGS excluding D&A 19.33B 17.24B 15.09B 14.74B 13.41B
Depreciation & Amortization Expense 2.2B 2.23B 2.38B 2.92B 3.07B
Depreciation 1.95B 1.99B 2.19B 2.72B 2.9B
Amortization of Intangibles 247.99M 239M 195.87M 195.63M 163.14M
Gross Income 5.28B 16.26B 20.29B 14.5B 16.26B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense - 1.38B 3.41B 5.73B 5.43B
Research & Development 123.67M 121.12M 92.32M 155.25M 147.78M
Other SG&A - 1.26B 3.32B 5.57B 5.28B
Other Operating Expense 719.61M 2.49B 2.93B 1.92B 2.03B
Unusual Expense 840.72M 531.11M 5.87B 10.21B 5.39B
EBIT after Unusual Expense (840.72M) (531.11M) (5.87B) (10.21B) (5.39B)
Non Operating Income/Expense 1.49B 1.28B 374.28M 1.52B (1.11B)
Non-Operating Interest Income 76.9M 105.58M 71.74M 73.21M 43.5M
Equity in Affiliates (Pretax) - - - - -
Interest Expense 754.85M 694.33M 724.23M 437.97M 554.67M
Gross Interest Expense 881.73M 812.22M 1.03B 921.37M 1.02B
Interest Capitalized 126.88M 117.88M 307.53M 483.41M 465.1M
Pretax Income 4.53B 12.56B 7.8B (2.2B) 1.8B
Income Tax 1.33B 3.43B 4.02B 371.71M 1.55B
Income Tax - Current Domestic 640,792 3.26B 3.82B 2.45B 2.62B
Income Tax - Current Foreign 1.66B 0 0 0 -
Income Tax - Deferred Domestic 0 174.88M 192.13M (2.08B) (1.07B)
Income Tax - Deferred Foreign (331.29M) 0 0 0 -
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 503.66M 713.12M 439.16M 666.42M 446.55M
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 3.71B 9.84B 4.23B (1.91B) 690.3M
Minority Interest Expense 296.69M 557.02M 585.75M 631,079 (1.65B)
Net Income 3.41B 9.28B 3.64B (1.91B) 2.34B
Extraordinaries & Discontinued Operations (287.72M) (62.83M) (6.24M) (4.42M) 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (287.72M) (62.83M) (6.24M) (4.42M) 0
Net Income After Extraordinaries 3.12B 9.22B 3.63B (1.91B) 2.34B
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 3.41B 9.28B 3.64B (1.91B) 2.34B
EPS (Basic) 2.78 4.70 1.89 (1.03) 1.27
Basic Shares Outstanding 1.76B 1.96B 1.92B 1.85B 1.85B
EPS (Diluted) 2.77 4.68 1.88 (1.03) 1.26
Diluted Shares Outstanding 1.77B 1.97B 1.94B 1.85B 1.86B
EBITDA 6.76B 14.62B 16.33B 9.77B 11.87B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 22

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 26

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 34

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 28

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 19

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 27

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

FTI Consulting Expands Tax Advisory Team with New Experts

Updated Category News Views 199

FTI Consulting Strengthens Tax Advisory Team FTI Consulting, Inc. (NYSE: FCN) has announced the strategic enhancement of its Tax Advisory team within the EMEA region through the recruitment of two highly experienced professionals. This move reflects the company's commitment to providing top-tier advisory services amidst the complexities of the global tax environment. New...

Continue Reading
Cingulate Inc. Unveils Q1 Financial Highlights and Future Plans

Updated Category News Views 148

Cingulate Inc. Reports First Quarter Financial Results Cingulate Inc. (NASDAQ: CING), a biopharmaceutical entity known for its innovative Precision Timed Release™ (PTR™) drug delivery technology, has recently unveiled its financial results for the first quarter. The report sheds light on several important developments concerning their lead assets for ADHD and anxiety....

Continue Reading
Innovative Partnership Propels Sen-Jam Pharmaceutical's Future

Updated Category News Views 106

Strategic Partnership to Enhance Phase 3 Trial for SJP-001 In a significant move, Sen-Jam Pharmaceutical has announced a promising partnership with TASK Clinical, a renowned global contract research organization (CRO), aimed at funding two-thirds of the upcoming Phase 3 clinical trial for its lead candidate, SJP-001. This equity-backed collaboration is not only innovative...

Continue Reading
Exploring the Future of Solar Energy: Insights from EnergySage

Updated Category News Views 231

EnergySage's Solar & Storage Marketplace Report Highlights EnergySage, a trusted name in solar market analysis, has released its latest report, which delves into the current dynamics of the solar and storage marketplace. This comprehensive analysis examines trends that are influencing the future of the industry, particularly in light of recent policy shifts. Residential...

Continue Reading
Investors' Rights: Explore Possible Violations for SCS, HLVX and Others

Updated Category News Views 166

Investigation into Potential Shareholder Violations Halper Sadeh LLC, a well-known law firm advocating for investor rights, is currently investigating several companies due to potential breaches of federal securities laws and fiduciary duties to their shareholders. Steelcase Inc. (SCS) Steelcase Inc. is reportedly undergoing a transaction involving the sale to HNI...

Continue Reading